Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can This Stock Double Again in 2026?

TheMotleyFool

0 0

Can This Stock Double Again in 2026?Photo, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Structure Therapeutics (NASDAQ: GPCR) ended 2025 on a strong note. Shares of the clinical-stage biotech soared in December after it reported strong mid-stage data for its leading pipeline candidate, an investigational weight loss medicine called aleniglipron. If Structure Therapeutics can make more progress toward entering the fast-growing anti-obesity market this year, we could see the company carrying the momentum it had last year through 2026.

But can the stock really deliver the kinds of returns it did last year? And is it worth investing in for those focused on the long game? Let's find out.

Image source: Getty Images.

Source Fool.com

Like: 0

GPCR

Share